Topics

Drug Delivery Systems Improve Cancer Immunotherapy

Cancer Immunotherapy Tumor Microenvironment Intercellular Communication & Diseases Cellular Stress

Drug delivery systems can improve cancer immunotherapy by controlling where, when, and in what combination immune agents are released. Nanoparticles, liposomes, polymer conjugates, micelles, hydrogels, scaffolds, and local depots can carry checkpoint inhibitors, cytokines, nucleic acids, vaccines, innate agonists, or conventional drugs. The aim is to raise exposure in tumor or lymphoid tissue while reducing systemic inflammation and organ toxicity. Delivery is particularly important for potent immune agonists whose effective and toxic doses overlap. Materials are not biologically neutral, however; size, charge, composition, degradation, and protein adsorption influence biodistribution and innate immunity, making the carrier part of the therapeutic mechanism The platform can also synchronize agents that require a specific sequence, such as tumor injury followed by innate sensing or checkpoint release[1][2][3].

Passive accumulation through abnormal tumor vessels is variable across patients and lesions. Active targeting adds ligands for tumor, endothelium, or immune-cell receptors, but receptor abundance and accessibility determine whether binding improves distribution or causes peripheral sequestration. Stimuli-responsive systems release cargo under acidic, enzymatic, hypoxic, or externally applied conditions. Lymph-node-targeted particles can enhance vaccine delivery to dendritic cells, while tumor-retained depots can sustain STING or Toll-like receptor agonism. Co-delivery fixes the ratio and timing of agents within one carrier, which may create synergy but also prevents independent dose adjustment. Endosomal escape and intracellular trafficking remain major barriers for RNA and protein cargo Corona formation in blood may hide a targeting ligand or redirect the particle, causing in vitro cell specificity to disappear after infusion[1][2].

Applications include localized cytokine release, nanoparticle vaccination, co-delivery of chemotherapy with checkpoint blockade, reprogramming of tumor-associated macrophages, and support of adoptive cell therapy. A hydrogel after tumor resection can treat a high-risk local site, whereas an intravenously administered carrier must navigate blood proteins, liver, spleen, kidney, and tumor vasculature. Manufacturing controls must define particle distribution, cargo loading, free drug, release kinetics, sterility, and stability. Immune toxicity can arise from both cargo and material through complement activation, infusion reactions, or unexpected organ accumulation. A sophisticated carrier is useful only if it improves a clinically meaningful therapeutic index Local systems avoid some distribution barriers but must account for diffusion, surgical placement, tissue pressure, and removal or biodegradation after cargo release[1][3].

Research gaps include poor prediction of human biodistribution, incomplete comparison with free drug, and publication bias toward successful formulations. Quantitative imaging and tissue sampling should show where each carrier and cargo actually travel. Models need intact immunity and realistic tumor architecture. Studies should compare equal active-drug exposure and report material-only controls, repeated-dose immunogenicity, degradation products, and scale-up reproducibility. Modular systems that allow cargo or targeting ligands to change without rebuilding the entire platform may accelerate translation. Delivery technology can unlock immunotherapies that are otherwise too toxic or unstable, but clinical success depends on reproducible exposure control rather than complexity for its own sake A clinically credible formulation should outperform a simpler schedule on efficacy, safety, convenience, or stability rather than only on preclinical uptake. Health-economic analysis should include reduced hospitalization or toxicity as potential benefits, since manufacturing expense alone does not define the platform’s value[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-17589 Chloroquine phosphate
Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
Parasite   Autophagy   SARS-CoV   Toll-like Receptor (TLR)   HIV   Antibiotic  
Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   SARS-CoV-2 Infection   Rheumatoid Arthritis  
1344
HY-17589A Chloroquine
Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
Parasite   Autophagy   SARS-CoV   Toll-like Receptor (TLR)   HIV   Antibiotic  
Breast Cancer   Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   SARS-CoV-2 Infection   Rheumatoid Arthritis  
1344
HY-D1056 Lipopolysaccharides, from E. coli O55:B5
Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be widely used to induce cellular inflammation and establish animal models related to inflammation.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

Source: surface of Gram-negative bacteria

Toll-like Receptor (TLR)  
Cancer   Pain   Autoimmune Disease   Escherichia Coli Infection  
616
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
Toll-like Receptor (TLR)   TNF Receptor   Interleukin Related   Autophagy  
Prostate Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
536
HY-100941 CCCP
CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
PINK1/Parkin   Oxidative Phosphorylation   STING   IFNAR   Mitochondrial Metabolism   Bacterial   Apoptosis  
Non-Small Cell Lung Cancer   Mycobacterium Tuberculosis Infection   Parkinson's Disease  
192
HY-B2176 ATP
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.

Source: widespread

Endogenous Metabolite   NOD-like Receptor (NLR)   Interleukin Related   Bacterial  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
178
HY-112693 H-151
H-151 is a potent, selective and covalent antagonist of STING that has noteworthy inhibitory activity both in cells and in vivo. H-151 reduces TBK1 phosphorylation and suppresses STING palmitoylation. H-151 can be used for the research of autoinflammatory disease.
STING  
Cancer   Inflammation or Immune System Disease  
168
HY-B0240 Disulfiram
Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu2+ increases intracellular ROS levels and induces cuproptosis.
Aldehyde Dehydrogenase (ALDH)   Interleukin Related   Pyroptosis   Apoptosis   Cuproptosis  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Autoimmune Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
161
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-112906 C-176
C-176 is a selective and blood-brain barrier permeable STING inhibitor. C-176 covalently targets transmembrane cysteine residue 91 and thereby blocking activation-induced palmitoylation of STING.
STING  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
127
HY-13740 Resiquimod
Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
Toll-like Receptor (TLR)   HCV  
Prostate Cancer   Viral Infection   Depression   Pain   Autoimmune Disease   SARS-CoV-2 Infection   Hepatitis C Virus Infection  
120
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-W031727 Hydroxychloroquine
Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling.
Parasite   Toll-like Receptor (TLR)   SARS-CoV   Autophagy  
Prostate Cancer   Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   Rheumatoid Arthritis  
95
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-14519 Methotrexate
Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Antifolate   Dihydrofolate reductase (DHFR)   NO Synthase   COX   Interleukin Related  
Breast Cancer   Arthritis   Systemic Lupus Erythematosus   Psoriasis   Lung Fibrosis  
87
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L080 Targeted Therapy Drug Library
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases. MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

Disease Focused Libraries

84
HY-L083 Anti-Cancer Metabolism Compound Library
Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth. MCE provides a unique collection of 3,806 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

Signaling Pathway Targeting Libraries

84
HY-L188 Anti-Brain Cancer Compound Library
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets. MCE designs a unique collection of 2,134 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
84
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L135 Cancer Stem Cells Compound Library
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on. Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment. MCE supplies a unique collection of 3,540 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Compound Characteristic Classified Libraries

83
HY-L161 Cytokine Inhibitors Library
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases. MCE designs a unique collection of 1,416 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.

Signaling Pathway Targeting Libraries

83
HY-L173 Anti-Ovarian Cancer Compound Library
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer. MCE designs a unique collection of 2,967 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Disease Focused Libraries

83
HY-L201 Cell Proliferation Compound Library
Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others. MCE collects 3,628 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.

Signaling Pathway Targeting Libraries

83
HY-L204 Lactic Acid Metabolic Compound Library
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism. MCE contains 582 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.
83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L214 Liposome Library
Liposomes are spherical or multilayered spherical vesicles formed by the self-assembly of diacyl chain phospholipids (lipid bilayers) in aqueous solutions, which can be made from natural or synthetic phospholipids and exhibit good biocompatibility and low toxicity. They can serve as delivery carriers for various bioactive substances (such as drugs, proteins, nucleic acids, etc.) and are widely used in biomedical and chemical research. The main advantages of liposomes include 1) Protective effect: Their bilayer structure can protect encapsulated molecules from enzymatic degradation, oxidation, and other influences, extending stability and activity; 2) Active targeting: Surface modifications enable active targeting, enhancing the concentration of drugs or molecules in specific tissues or cells; 3) Customizability: The composition and structure of liposomes can be adjusted according to needs, such as altering phospholipid types or adding targeting ligands. These properties make liposomes highly valuable in developing novel drug delivery systems, serving as nucleic acid carriers for gene transfection, studying cellular uptake mechanisms and drug release kinetics, as well as developing functional food additives to improve the bioavailability of nutritional components. MCE contains 227 liposome compounds, which is a good tool for drug delivery-related studies.
83
HY-L251 Ionizable Lipid Compound Library
Ionizable lipids are a class of specialized, functional lipid molecules with pH-sensitive charge characteristics. They are primarily divided into two major categories: ionizable cationic lipids and ionizable anionic lipids, though the term typically specifies ionizable cationic lipids within the biomedical field. Structurally, these lipids consist of an ionizable hydrophilic headgroup, a biodegradable linker, and hydrophobic tails. Their primary application is serving as the key delivery vehicle in lipid nanoparticles (LNPs) to encapsulate negatively charged nucleic acid macromolecules, such as mRNA vaccines, siRNA therapeutics, and CRISPR gene-editing components. In a physiological, neutral environment, they remain electrically neutral to minimize systemic toxicity and prolong circulation time. Upon entering the acidic microenvironment of cellular endosomes, however, they undergo protonation to become positively charged, thereby inducing membrane fusion and enabling the highly efficient intracellular release of the nucleic acid cargo. Consequently, they serve as the technological cornerstone for bringing nucleic acid therapies into clinical application. To accelerate the translational process of cutting-edge nucleic acid drugs, MCE has meticulously constructed an ionizable lipid compound library containing 93 high-performance molecules, aiming to provide researchers and pharmaceutical professionals with a high-throughput, multi-dimensional lipid screening platform.

Structure Classified Libraries

83
HY-L256 Azide Compound Library
In modern drug discovery and chemical biology research, the azide group (-N3) is an important functional moiety that is widely used in click chemistry, biomolecular labeling, drug delivery systems, and prodrug design due to its unique reactivity and bioorthogonality. The MCE Azide Structural Compound Library contains 100 compounds featuring -N3 functional groups. It is designed for the construction of click chemistry reaction systems and the subsequent development of functional molecules. This library enables the rapid assembly of targeting ligands, linkers, and functional molecular modules, thereby accelerating PROTAC assembly, optimization of antibody-drug conjugate (ADC) linkers, and the development of biological labeling probes. In addition, the high reaction selectivity and excellent biocompatibility of the azide group allow it to maintain stable reactivity even in complex biological environments, improving controllability and efficiency in drug design. It serves as an indispensable molecular tool in modern medicinal chemistry and chemical biology research.

Compound Characteristic Classified Libraries

83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-10964 Vadimezan
Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
STING   IFNAR   Influenza Virus  
Prostate Cancer   Viral Infection   Autoimmune Disease   Non-Small Cell Lung Cancer  
80
HY-N1446A Glycerol Monoleate
Glycerol Monoleate is a non-toxic, biodegradable, biocompatible, lipophilic glycerol fatty acid ester. Glycerol Monoleate exhibits hemolytic properties. Glycerol Monoleate is combined with bile salts for use as an emulsifier and absorption enhancer. Glycerol Monoleate can be applied in drug delivery systems and in vitro siRNA delivery.
Endogenous Metabolite  
75
HY-135748 Polyinosinic-polycytidylic acid sodium
Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis.
RIG-I-like receptor (RLR)   Toll-like Receptor (TLR)   Apoptosis  
Cancer   Digestive System Disease   Pain   Autoimmune Disease   Digestive System Inflammation   Lung Fibrosis  
75
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-107202 Polyinosinic-polycytidylic acid
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
RIG-I-like receptor (RLR)   Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Digestive System Disease   Prostate Cancer   Pain   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
73
HY-B0180 Imiquimod
Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Toll-like Receptor (TLR)   Autophagy   SARS-CoV   HSV  
Inflammation or Immune System Disease   Metastatic Breast Cancer   SARS-CoV-2 Infection  
62
HY-108841 Raleukin
Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction.

Species: Human

Interleukin Related  
Metastatic Breast Cancer   SARS-CoV-2 Infection   Rheumatoid Arthritis  
57
HY-112921A diABZI STING agonist-1
diABZI STING agonist-1 is a tautomerism of diABZI STING agonist-1 tautomerism (HY-112921). diABZI STING agonist-1 is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively.
STING  
Cancer   Inflammation or Immune System Disease   Neurodegenerative Disease  
52
HY-B1081A Oxidopamine hydrobromide
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
Dopamine Receptor   Autophagy   Mitophagy   COX   PGE synthase   Interleukin Related   p38 MAPK   Apoptosis   Caspase  
Breast Cancer   Parkinson's Disease  
50
HY-100564A 2',3'-cGAMP sodium
2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP sodium binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm.
Endogenous Metabolite   STING   IFNAR  
Metabolic or Endocrine Disease  
44
HY-100564 2',3'-cGAMP
2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm.
Endogenous Metabolite   STING   IFNAR  
Metabolic or Endocrine Disease  
44
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-126304 β-Glycerophosphate disodium salt hydrate
β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells.
Phosphatase   Endogenous Metabolite   ERK  
Metabolic or Endocrine Disease   Pancreatic Cancer   Depression   Pain   Lung Fibrosis  
35
HY-136927 MSA-2
MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models.
STING  
Cancer   Inflammation or Immune System Disease  
35
HY-D0886 β-Glycerophosphate disodium salt pentahydrate
β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells.
Phosphatase   Endogenous Metabolite   ERK  
Cancer   Metabolic or Endocrine Disease  
35
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-13902 Berzosertib
Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer.
ATM/ATR   Apoptosis   STING   Caspase  
Pancreatic Cancer   Ovarian Cancer   SARS-CoV-2 Infection   Obesity  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-12212 Omaveloxolone
Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates Nrf2 and suppresses nitric oxide (NO). Omaveloxolone attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.
Keap1-Nrf2   STING   Apoptosis  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity   Lung Fibrosis  
26
HY-153808 Complete Freund's adjuvant (CFA)
Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
25
HY-N7131 Coumarin 6
Coumarin 6, a fluorescent dye, is used as a fluorescent probe in a microparticle drug delivery system to conduct in vivo tracking, cell uptake, and transport mechanism studies of drug delivery systems (λexc=450 nm, λem=505 nm).
Fluorescent Dye  
24
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P1439A RS 09 TFA
RS 09 TFA is an LPS (HY-D1056) peptide mimic and TLR4 agonist. RS 09 TFA can bind to TLR-4 and activate NF-κB. RS 09 TFA can function as an adjuvant in vivo, enhancing the antigen-specific immune response.
Toll-like Receptor (TLR)   NF-κB  
Pancreatic Cancer   Pain   Autoimmune Disease   Digestive System Inflammation  
22
HY-A0129 Histamine phosphate
Histamine phosphate is the agonist for histamine receptor and a vasodilator. Histamine phosphate is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine phosphate affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine phosphate can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma.
Histamine Receptor   Reactive Oxygen Species (ROS)   Akt   Endogenous Metabolite   p38 MAPK   Apoptosis  
Metabolic or Endocrine Disease   Lung Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   SARS-CoV-2 Infection   Hypertension  
22
HY-B0722 Histamine dihydrochloride
Histamine dihydrochloride is the agonist for histamine receptor and a vasodilator. Histamine dihydrochloride is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine dihydrochloride affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine dihydrochloride can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma.
Histamine Receptor   Reactive Oxygen Species (ROS)   Akt   Endogenous Metabolite   p38 MAPK   Apoptosis  
Metabolic or Endocrine Disease   Digestive System Disease   Leukemia/Lymphoma/Myeloma   Neurodegenerative Disease   Depression   Digestive System Inflammation   Non-Small Cell Lung Cancer   Hypertension  
22
HY-P1439 RS 09
RS 09 is an LPS (HY-D1056) peptide mimic and TLR4 agonist. RS 09 can bind to TLR-4 and activate NF-κB. RS 09 can function as an adjuvant in vivo, enhancing the antigen-specific immune response.
Toll-like Receptor (TLR)   NF-κB  
Inflammation or Immune System Disease  
22
HY-B1204 Histamine
Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma.
Histamine Receptor   Reactive Oxygen Species (ROS)   Akt   Endogenous Metabolite   p38 MAPK   Apoptosis  
Metabolic or Endocrine Disease   Lung Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   SARS-CoV-2 Infection   Hypertension  
22
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-D0040 Calcein
Calcein is a fluorescent dye and self-quenching probe, used as an indicator of lipid vesicle leakage, and also as a complexometric indicator for titration of calcium ions with EDTA, and for fluorometric determination of calcium. Calcein cannot directly cross the intact cell membrane of a living cell, unlike Calcein-AM (HY-D0041) which is cell-permeable. Calcein can also be used as a model drug for evaluating efficiency and bioavailability of drug delivery systems.
Fluorescent Dye  
15
HY-P9926 Dupilumab
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Breast Cancer   Non-Small Cell Lung Cancer   Staphylococcus Aureus Infection  
9
HY-P99974 Nab-Paclitaxel
Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11).
Microtubule/Tubulin   Apoptosis   Autophagy  
Non-Small Cell Lung Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
8
HY-P0122 iRGD peptide
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
Integrin  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-W250978 Ovalbumins
Ovalbumins are the major proteins in egg white. Ovalbumins act as an allergen and inducer, and can be applied to mouse models of allergic diseases. Ovalbumins can induce allergic rhinitis in mice via sensitization and nasal challenge. Ovalbumins can be used to establish asthma models.
Ovalbumin, low endotoxin (HY-W250978A) is recommended for model establishment.
Interleukin Related   IFNAR  
Allergic Asthma   Allergic Rhinitis  
6
HY-150524 UDP-Galactose
UDP-Galactose is a monosaccharide and a key glycosyl donor molecule in cells that participates in nucleotide sugar metabolism. UDP-Galactose is the natural agonist of the P2Y14 receptor coupled to Gi proteins in the immune system (IC50 = 0.67 μM, hP2Y14). UDP-Galactose can be used to study cell signal transduction and substance metabolism.
Endogenous Metabolite   P2Y Receptor  
Metabolic or Endocrine Disease  
5
HY-113414 Deoxycorticosterone
Deoxycorticosterone is a steroid hormone produced by the adrenal gland that possesses mineralocorticoid activity and acts as an aldosterone precursor. Deoxycorticosterone is an agonist for O. mykiss mineralocorticoid receptor (rtMR) transcription with EC50 of 0.16 nM. Deoxycorticosterone could acts as an immune stimulator in fish.
Endogenous Metabolite   Mineralocorticoid Receptor  
Inflammation or Immune System Disease  
5
HY-114364 UDP-Galactose disodium
UDP-Galactose disodium is a monosaccharide and a key glycosyl donor molecule in cells that participates in nucleotide sugar metabolism. UDP-Galactose disodium is the natural agonist of the P2Y14 receptor coupled to Gi proteins in the immune system (IC50 = 0.67 μM, hP2Y14). UDP-Galactose disodium can be used to study cell signal transduction and substance metabolism.
Endogenous Metabolite   P2Y Receptor  
Metabolic or Endocrine Disease  
5
HY-P1844 Chemerin-9 (149-157)
Chemerin-9 (149-157) is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) has anti-inflammatory activity. Chemerin-9 (149-157) stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) ameliorates Aβ1-42-induced memory impairmen. Chemerin-9 (149-157) regulates immune responses, adipocyte differentiation, and glucose metabolism.
Chemerin Receptor   Akt   ERK   Reactive Oxygen Species (ROS)   Amyloid-β  
Inflammation or Immune System Disease  
4
HY-P1844A Chemerin-9 (149-157) TFA
Chemerin-9 (149-157) TFA is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) TFA has anti-inflammatory activity. Chemerin-9 (149-157) TFA stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) TFA ameliorates Aβ1-42-induced memory impairmen. Chemerin-9 (149-157) TFA regulates immune responses, adipocyte differentiation, and glucose metabolism.
Chemerin Receptor   Akt   ERK   Reactive Oxygen Species (ROS)   Amyloid-β  
Breast Cancer   Pancreatic Cancer   Pain   Digestive System Inflammation   Alzheimer's Disease  
4
HY-32350 Ercalcitriol
Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
VD/VDR   Drug Metabolite   Endogenous Metabolite  
Metabolic or Endocrine Disease  
3
HY-164992 Trastuzumab vedotin
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma.
Antibody-Drug Conjugates (ADCs)   EGFR   Microtubule/Tubulin  
Gastric Cancer   Metastatic Breast Cancer   Urothelial Cancer  
3
HY-P1848 Pep-1 (uncapped)
Pep-1 (uncapped) is a specific ligand of IL-13Ra2. Pep-1 (uncapped) exerts cell penetrating activity through receptor-mediated endocytosis, can cross the blood-tumor barrier (BTB) and target glioma cells. Pep-1 (uncapped) can enhance the uptake of nanoparticles by tumor cells and enhance the cell penetration ability of nanoparticles, and can be used to develop targeted drug delivery systems for glioma.
Interleukin Related  
Cancer  
2
HY-106033 Edotreotide
Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as 90Y, 177Lu, and 68Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs).
Radionuclide-Drug Conjugates (RDCs)  
Lung Cancer  
2
HY-W053583 Tetraxetan
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
Biochemical Assay Reagents   Radionuclide-Drug Conjugates (RDCs)  
Cancer  
2
HY-P99279 Bavituximab
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer.

Species: Human

Others  
Gastric Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
2
HY-119109 Laminaran
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.

Source: Eisenia Bicyclis

Environmental Pollutants   C-type Lectin-like Receptors (CTLRs)   Endogenous Metabolite  
Colorectal Cancer  
2
HY-W013508 I2959
I2959 is widely used as a photoinitiator for photochemical cross-linking of hydrogels, and the combination of I2959 and CMA hydrogel has been used as a bio-ink for biological 3D printing applications. In addition, I2959 has a high free radical generation efficiency and is cytotoxic to rapidly dividing cell lines.
Biochemical Assay Reagents  
2
HY-D1375A Sulfo-Cy5 amine hydrochloride
Sulfo-Cy5 amine hydrochloride is a Cyanine 5 (Cy5) (HY-D0821) dye derivative with an amine group. Sulfo-Cy5 amine hydrochloride can endow silica nanoparticles with fluorescent properties, be internalized by cancer cells, and exhibit enhanced photostability after being incorporated into silica nanoparticles. Its maximum excitation wavelength is approximately 646 nm, and maximum emission wavelength is approximately 662 nm.
Fluorescent Dye  
1
HY-B1204S1 Histamine-d4
Histamine-d4 (Ergamine-d4) is deuterium labeled Histamine (HY-B1204). Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma.
Isotope-Labeled Compounds   Akt   Endogenous Metabolite   p38 MAPK   Apoptosis   Histamine Receptor   Reactive Oxygen Species (ROS)  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-15306S Eltrombopag-13C4
Eltrombopag-13C4 (SB-497115-13C4) is 13C-labeled Eltrombopag. Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells.
Thrombopoietin Receptor   Bacterial   Apoptosis  
Cancer   Blood or Cardio-cerebrovascular Disease   Staphylococcus Aureus Infection  
1
HY-10087S Navitoclax-d8
Navitoclax-d8 is the d8-labeled Navitoclax (HY-10087). Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases.
Isotope-Labeled Compounds   Bcl-2 Family   Apoptosis   Survivin   TGF-β Receptor  
Ovarian Cancer   Triple-Negative Breast Cancer   Acute Lymphoblastic Leukemia   Platelet Disease  
1
HY-W001158 N,N-Dimethylglycine hydrochloride
N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects.
Free Radical Scavengers   iGluR   Endogenous Metabolite   Amino Acid Derivatives  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
1
HY-163001 Microcolin H
Microcolin H is a marine lipopeptide and phosphatidylinositol transfer protein ligand that targets PITPα/β. Microcolin H increases the conversion of LC3I to LC3II and reduces p62 levels in cancer cells, leading to autophagy cell death (Autophagy). Microcolin H effectively inhibits tumor development and has anti-proliferative activity in nude mouse subcutaneous tumor models.

Source: Moorea producens

Autophagy   Atg8/LC3   p62  
Cancer  
1
HY-N5084 Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
TRP Channel   HDAC   p38 MAPK   JNK   ERK   NF-κB   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Bladder Cancer   Pain  
1
HY-P99812 Ragifilimab
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
1
HY-N6924 Zingibroside R1
Zingibroside R1 is an orally active triterpene saponin with multiple biological activities including antioxidant, anti-inflammatory, antiviral, and metabolic regulatory properties. Zingibroside R1 reduces the expression of PIN family members, inhibits the expression of PLT1/PLT2, WOX5, SHR, and SCR, disrupts auxin transport and distribution, triggers plant ROS responses, and inhibits root growth. Zingibroside R1 extends the lifespan of Caenorhabditis elegans, enhances its heat stress resistance, and improves its motor ability. Hydrogel derivatives of Zingibroside R1 inhibit the proliferation of Candida albicans by binding to its β-1,3-glucan and exhibit antifungal activity. Zingibroside R1 inhibits GLUT1-mediated uptake and alleviates liver injury. Zingibroside R1 can be used in research related to neurodegenerative diseases, vulvovaginal candidiasis, acute liver injury, Ehrlich ascites tumor and HIV-1 infection.
HIV   PIN1   Fungal   GLUT   Reactive Oxygen Species (ROS)  
Cancer   Metabolic or Endocrine Disease   Viral Infection   Neurodegenerative Disease   Candida Infection   Liver Injury  
1
HY-N6046 Kamebakaurin
Kamebakaurin is an orally active diterpenoid compound that can be isolated from Isodon excia (Maxin.). Kamebakaurin can inhibit NF-κB activation by directly targeting the DNA-binding activity of p50. Kamebakaurin can induce apoptosis and cell cycle arrest in tumor cells. Kamebakaurin has anti-inflammatory and anti-tumor activities.
NF-κB   Apoptosis   Caspase   HIF/HIF Prolyl-Hydroxylase  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity  
1
HY-N0381 Maackiain
Maackiain (DL-Maackiain) is an orally active multi-target inhibitor with anti-tumor activity and neuroprotective effects. Maackiain activates the AMPK, NLRP3 and Nrf2/HO-1 pathways, and inhibits key targets such as NF-κB, mTOR, MAO-B, NFATc1 and PKCδ, thereby precisely regulating processes including apoptosis, autophagy and pyroptosis. Maackiain also effectively inhibits microglial activation, osteoclast formation, and proliferation and invasion of tumor cells, and protects dopaminergic neurons from damage. Maackiain is applicable to the research of various diseases such as Alzheimer's disease, osteoporosis, sepsis and dengue fever。
Keap1-Nrf2   p38 MAPK   NOD-like Receptor (NLR)   NF-κB   mTOR   Monoamine Oxidase   Nuclear Factor of activated T Cells (NFAT)   PKC   Apoptosis   Pyroptosis   Autophagy   Dengue Virus  
Flavivirus Infection   Alzheimer's Disease   Osteoporosis  
1
HY-N5139 Lecithins, egg
Lecithins, egg (Lecithins, egg yolk; Belovo PL 85) is an orally active natural phospholipid mixture extracted from egg yolks. Lecithins, egg inhibits the activities of acetylcholinesterase (AChE) and angiotensin-converting enzyme (ACE). Lecithins, egg exhibits antibacterial, antioxidant and anti-inflammatory activities, and helps delay cellular senescence. Lecithins, egg enhances nerve conduction, improves memory and cognitive function, and exerts positive effects on delaying neurodegenerative diseases. Lecithins, egg promotes lipid absorption and alleviates diarrhea. Lecithins, egg acts as a high-efficiency drug carrier for the preparation of targeted drug delivery systems such as liposomes.
Cholinesterase (ChE)   Angiotensin-converting Enzyme (ACE)   Bacterial  
Digestive System Disease   Bacterial Infection   Neurodegenerative Disease   Oxidative Stress and Inflammation   Lipid Metabolism  
1
HY-D1375 Sulfo-Cy5 amine
Sulfo-Cy5 amine is a Cyanine 5 (Cy5) (HY-D0821) dye derivative with an amine group. Sulfo-Cy5 amine can endow silica nanoparticles with fluorescent properties, be internalized by cancer cells, and exhibit enhanced photostability after being incorporated into silica nanoparticles. Its maximum excitation wavelength is approximately 646 nm, and maximum emission wavelength is approximately 662 nm.
Fluorescent Dye  
1
HY-W105804 Selenocystamine dihydrochloride
Selenocystamine dihydrochloride is a selenocysteine derivative that can be used in the synthesis of other active compounds. Selenocystamine dihydrochloride can also induce the aggregation of amphiphilic p-sulfonatocalixarene to form supramolecular nanoparticles.
Amino Acid Derivatives   Drug Intermediate  
1
HY-P10128 GE11
GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
1
HY-Y0511 N,N-Dimethylglycine
N,N-Dimethylglycine (Dimethylglycine), a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine has antidepressant-like and surfactant effects.
Free Radical Scavengers   Endogenous Metabolite   iGluR   Amino Acid Derivatives  
Metabolic or Endocrine Disease   Depression  
1
HY-143712 Allolithocholic acid
Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease.
Drug Metabolite   G protein-coupled Bile Acid Receptor 1   ROR  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-168968S ZJY-54
ZJY-54 is an orally active dual-target inhibitor of EGFR/LSD1, with IC50 values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity.
EGFR   Histone Demethylase  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-P1120A WKYMVm TFA
WKYMVm (TFA) is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs, and WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor.
Formyl Peptide Receptor (FPR)   PERK   Apoptosis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-D2281 FAP Ligand 2
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging.
FAP  
/
HY-138134 NOTP
NOTPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTP can be used for conjugation of peptides and radionuclides.
Biochemical Assay Reagents   MOFs   Radionuclide-Drug Conjugates (RDCs)  
Cancer  
/
HY-N15786 DSPE-RGD Lipid sodium
DSPE-RGD Lipid sodium is a lipid containing DSPE and RGD peptides that can be used to prepare lipid nanoparticles for drug delivery.
Biochemical Assay Reagents  
Cancer  
/
HY-P991556 TQB2916
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research.

Species: Human

TNF Receptor  
Cancer  
/
HY-P992368 HLX51
HLX51 is a regulatory T cell inhibitor and OX40/CD134/TNFRSF4 agonist with tumour growth inhibitory activity. HLX51 inhibits regulatory T cell differentiation and activity, relieves tumour microenvironment immunosuppression, enhances effector T cell function. HLX51 competitively binds OX40, activates OX40, promotes immune cell proliferation and T cell killing ability. HLX51 modulates immune cell function to inhibit tumour growth. HLX51 can be used for the research of advanced/metastatic solid tumours and lymphomas.

Species: Human

TNF Receptor  
Leukemia/Lymphoma/Myeloma  
/
HY-N16420 Illudin B
Illudin B is a DNA-targeting cytotoxin that forms interstrand DNA crosslinks via covalent binding, disrupting DNA replication and transcription. Illudin B induces cell cycle arrest and apoptosis, showing toxicity against multiple tumor cells (e.g., leukemia, breast, lung cancer).

Source: Basidiomycete Omphalotus nidiformis

DNA/RNA Synthesis   Apoptosis  
/
HY-P11281 GYGGGP(GPP)5GFOGER(GPP)5GPC
GYGGGP(GPP)5GFOGER(GPP)5GPC is a type I collagen mimic that can bind to integrins and modify hydrogels.
Others  
Inflammation or Immune System Disease  
/
HY-N9826 Icterogenin
Icterogenin is a selective inhibitor targeting the Bcl-XL/Bak BH3 domain peptide interaction and exhibits anti-leukemic activity. Icterogenin regulates protein interactions and affects tumor cell survival. Icterogenin is an oleanane-type triterpenoid compound that can be isolated from Lantana camara and is useful in the field of anti-tumor drug development.
Bcl-2 Family  
Leukemia/Lymphoma/Myeloma  
/
HY-W087027A Maleimide-NOTA TFA
Maleimide-NOTA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. Maleimide-NOTA (TFA) can be used for conjugation of peptides and radionuclides.
Biochemical Assay Reagents   Radionuclide-Drug Conjugates (RDCs)  
/
HY-P10675 Peptide K
Peptide K is a self-assembling peptide fiber that can be used to prepare fibrous nanocomposite hydrogels. The fibrous nanocomposite hydrogels have a dynamic network that adapts to cells and enhances cell-matrix and cell-cell interactions, thus significantly promoting the mechanotransduction, metabolic energy, and osteogenesis of encapsulated stem cells.
Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-P992458 SBT8230 Antibody
SBT8230 Antibody is the antibody moiety of SBT8230, and belongs to anti-ASGR1 antibodies. SBT8230 is an ASGR1-targeted TLR8 agonist, which acts as an ASGR1-TLR8 immune-targeting antibody conjugate (ISAC). SBT8230 activates myeloid cells and induces anti-HBV immune responses. SBT8230 is applicable to research on chronic hepatitis B infection. The isotype control for SBT8230 Antibody is Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Phosphatase  
Hepatitis B Virus Infection  
/
HY-P11205 Cys-PKHB1
Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
CD47   Reactive Oxygen Species (ROS)   Thrombopoietin Receptor  
Inflammation or Immune System Disease  
/
HY-P991406 MK-1248
MK-1248 is a human IgG4 monoclonal antibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research.

Species: Human

TNF Receptor  
Cancer  
/
HY-N2546 (+)-Dehydroabietic acid
(+)-Dehydroabietic acid is a diterpenoid. (+)-Dehydroabietic acid can be used for the acrylamide Hydrogel synthesis.
Others  
/
HY-D2132 Sulfo-Cy5.5-ALN
Sulfo-Cy5.5-ALN is a fluorescent labeled alendronate, which targets bone. Sulfo-Cy5.5-ALN binds to hydroxyapatite and differentiated osteoblasts in vitro. Sulfo-Cy5.5-ALN selectively binds to the mineralized areas of the tumor. Sulfo-Cy5.5-ALN can be used to detect bone overgrowth in prostate bone metastasis.
Fluorescent Dye  
Cancer  
/
HY-N15951 C16 Ceramide-suc-PEG2K-maleimide
C16 Ceramide-suc-PEG2K-maleimide is functionalized PEG lipid that can be used to synthesize lipid nanoparticles for drug delivery.
Liposome  
/
HY-141613S (2S,8R,19Z)1,2-Dioleoyl-sn-glycero-3-phospho-L-serine-d3 ammonium
(2S,8R,19Z)1,2-Dioleoyl-sn-glycero-3-phospho-L-serine-d3 ammonium ((2S,8R,19Z)DOPS-d3 ammonium) is the deuterium labeled (2S,8R,19Z)1,2-Dioleoyl-sn-glycero-3-phospho-L-serine ammonium (HY-141613). 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine sodium (DOPS-NA) is a ubstitute for Phosphoserine/phosphatidylserine. 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine sodium can be used together with DOPC and DOPE in lipid mixtures for the synthesis of liposomes. 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine sodium can self-assemble into single-layer or double-layer membrane structures, similar to cell membranes, and possesses high membrane fluidity and flexibility. 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine is widely applied in membrane biology, cell membrane research, lipid preparation, and drug delivery systems.
Isotope-Labeled Compounds  
/
HY-P11799 cLABL
cLABL is a cyclic peptide that specifically binds to ICAM‑1. cLABL mediates targeted enrichment and rapid endocytosis of nanoparticles. cLABL is applicable to researches such as precise drug delivery at inflammatory sites.
Transmembrane Glycoprotein  
Inflammation or Immune System Disease  
/
HY-P10560 M918
M918 is a cell-penetrating peptide. M918 is internalized by cells through endocytosis and can effectively penetrate a variety of cells in a non-toxic manner. M918 can be used in gene therapy and drug delivery system research.
Biochemical Assay Reagents  
/
HY-143712R Allolithocholic acid (Standard)
Allolithocholic acid (Standard) is the analytical standard of Allolithocholic acid (HY-143712). This product is intended for research and analytical applications. Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease.
Reference Standards   Drug Metabolite   G protein-coupled Bile Acid Receptor 1   ROR  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P992344 DNP002
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated CEACAM6. DNP002 binds to CEACAM1, CEACAM5 and CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6 on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-W001158S1 N,N-Dimethylglycine-d3 hydrochloride
N,N-Dimethylglycine-d3 (Dimethylglycine-d3) hydrochloride is the deuterium labeled N,N-Dimethylglycine hydrochloride (HY-W001158). N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects.
Isotope-Labeled Compounds   Endogenous Metabolite   iGluR   Amino Acid Derivatives  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P11662 NLS peptide
NLS peptide is a nuclear localization signal peptide, a short amino acid sequence that can be recognized by nuclear transport machinery (such as the Importin protein complex). NLS peptide can directionally transport the molecules or nanoparticles linked to it into the nucleus, and the N-terminal Cys terminus can be used for subsequent coupling. NLS peptide can be used to construct nucleus-specific imaging probes and nucleus-targeted nanoparticles
Others  
Cancer  
/
HY-158077 (R)-tetraMe-Tetraxetan
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.
Biochemical Assay Reagents  
/
HY-D3353 PSMA-SulfoCy7
PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a Ki of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies.
PSMA  
Prostate Cancer  
/
HY-N7434S N-Nitrosodiethylamine-d4
N-Nitrosodiethylamine-d4 is the deuterium labeled N-Nitrosodiethylamine. N-Nitrosodiethylamine (Diethylnitrosamine) is a potent hepatocarcinogenic dialkylnitrosoamine. N-Nitrosodiethylamine is mainly present in tobacco smoke, water, cheddar cheese, cured, fried meals and many alcoholic beverages. N-Nitrosodiethylamine is responsible for the changes in the nuclear enzymes associated with DNA repair/replication. N-Nitrosodiethylamine results in various tumors in all animal species. The main target organs are the nasal cavity, trachea, lung, esophagus and liver.
DNA/RNA Synthesis  
Cancer  
/
HY-N9722 Dehydroherbarin
Dehydroherbarin is a selective inhibitor targeting HSP90α with blood-brain barrier penetration. Dehydroherbarin interferes with key pathways of tumor cell survival by binding to HSP90α, while exerting moderate antibacterial and anti-hepatitis A virus activities and inhibiting tumor cell migration. Dehydroherbarin can be used in research on tumors such as breast cancer.

Source: endophytic Chaetosphaeronema sp. (KY321184)

HSP  
Breast Cancer  
/
HY-W040193S2 DSPC-d79
DSPC-d79 (1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d79) is the deuterium labeled DSPC (HY-W040193). DSPC is a cylindrical-shaped lipid. 1,2-Distearoyl-sn-glycero-3-phosphorylcholine is used to synthesize liposomes, and is the lipid component in the lipid nanoparticle (LNP) system.
Isotope-Labeled Compounds   Liposome  
/
HY-P4089 REA
REA is a homing peptide that targets pre-cancerous tumor lymphatic vessels. REA homes to lymphatic vessels at the pre-cancerous tumor stage, but does not recognize tumor lymphatic vessels. REA can be used in pre-cancerous tumor research.
Others  
Cancer  
/
HY-P11886 GNYTCEVTELTREGETIIELK-N3
GNYTCEVTELTREGETIIELK-N3 (GNYTCEVTELTREGETIIELK-Azide) is a conjugate of an azide (-N3) group and a CD47 functional peptide (GNYTCEVTELTREGETIIELK). Modifying the surface of LNPs with GNYTCEVTELTREGETIIELK significantly reduces the recognition and clearance of LNPs by the mononuclear phagocytic system (MPS) and reduces their accumulation in non-target tissues such as the liver and spleen. The azide group in GNYTCEVTELTREGETIIELK-N3 can undergo click chemistry reactions for applications such as constructing targeted drug delivery systems and nanoparticle modification.
Biochemical Assay Reagents  
/
HY-W775262S Δ9-Tetrahydrocannabinolic acid-d3
Δ9-Tetrahydrocannabinolic acid-d3 is the deuterium labeled Δ9-Tetrahydrocannabinolic acid. Δ9-Tetrahydrocannabinolic acid is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.
Isotope-Labeled Compounds  
/
HY-P1813 PSA1 (141-150)
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments.
Prostaglandin Receptor  
/
HY-P992518 Pumitamig (Mouse IgG2a)
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-168943 PLGA nanoparticles, 100nm
PLGA nanoparticles, 100nm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 100nm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 100nm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 100nm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research.
Biochemical Assay Reagents  
Cancer  
/
HY-141629S1 N-Palmitoyl-D-sphingomyelin-13C
N-Palmitoyl-D-sphingomyelin-13C is a deuterated labeled N-Palmitoyl-D-sphingomyelin. N-Palmitoyl-D-sphingomyelin (Sphingomyelin 16:0) (Compound SM-03) can be used for the synthesis of lipid nanoparticles.
Isotope-Labeled Compounds   Endogenous Metabolite   Liposome  
/
HY-P11746 GPLGIAGQC
GPLGIAGQC is an MMP2-cleavable peptide. In nanoparticle-drug conjugation systems, GPLGIAGQC is cleaved by MMP2 between the glycine and isoleucine residues. After MMP2-mediated hydrolysis of GPLGIAGQC, the Fc fragment is exposed on the surface of nanoparticles.
MMP  
Cancer  
/
HY-126721 Tetralysine
Tetralysine is a cationic moietie that may be used in the construction of gene delivery vectors and DNA nanoparticles.
Biochemical Assay Reagents  
/
HY-D2979 OBADC-TPA
OBADC-TPA is a new type of photosensitizer. OBADC-TPA is commonly used to modify nanoparticles. OBADC-TPA can be used for precise optical imaging and research of lymphoma.
Photosensitizer  
/
HY-P992051 Anti-CD103 Antibody (hCD103.01A)
Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Integrin  
Cancer   Inflammation or Immune System Disease  
/
HY-D0886R β-Glycerophosphate disodium salt pentahydrate (Standard)
β-Glycerophosphate disodium salt pentahydrate (Standard) is the analytical standard of β-Glycerophosphate disodium salt pentahydrate (HY-D0886). This product is intended for research and analytical applications. β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells.
Reference Standards   Phosphatase   Endogenous Metabolite   ERK  
/
HY-D2314 Cyanine 7-amine chloride hydrochloride
Cyanine 7-amine (chloride hydrochloride) can be used to label cationic nanoparticles (NPs) or to NP conjugates (NPCs). It can track the residence time and clearance of nanoparticles in the body.
Liposome  
/
HY-143712S1 Allolithocholic Acid-d4
Allolithocholic Acid-d4 (3α-hydoxy-5α-Cholaoic Acid-d4, allo-LCA-d4) is deuterium labeled Allolithocholic acid (HY-143712). Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease.
Isotope-Labeled Compounds   Drug Metabolite   G protein-coupled Bile Acid Receptor 1   ROR  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N15803 DOPE-RGD Lipid sodium
DOPE-RGD Lipid sodium is a lipid containing DOPE and RGD peptides that can be used to prepare lipid nanoparticles for drug delivery.
Biochemical Assay Reagents  
Cancer  
/
HY-151998S DMPG-d54
DMPG-d54 is the deuterium labeled DMPG (1,2-Dimyristoyl-sn-glycero-3-phosphatidylglycerol). DMPG is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.
Isotope-Labeled Compounds  
/
HY-159176 Antitumor agent-183
Antitumor agent-183 (compound 3f) has antitumor activity with metabolic stability. Antitumor agent-183 inhibits cancer cell growth, with IC50s less than 5 nM for A549, HCT116, and HS578T cells. The albumin-bound nanoparticle formulation of Antitumor agent-183 has prolonged retention in the tumor tissues.
Cytochrome P450  
/
HY-W006371R (2-Aminoethyl)phosphonic acid (Standard)
(2-Aminoethyl)phosphonic acid (Standard) is the analytical standard of (2-Aminoethyl)phosphonic acid (HY-W006371). This product is intended for research and analytical applications. (2-Aminoethyl)phosphonic acid is an endogenous metabolite and amino acid analog. (2-Aminoethyl)phosphonic acid can be used for the synthesis of biological macromolecules and the preparation of hydrogels.
Reference Standards   Endogenous Metabolite   Drug Intermediate  
Metabolic or Endocrine Disease  
/
HY-P992473 TAS266
TAS266 is a tetrameric nanobody agonist targeting DR5. TAS266 selectively induces cancer cell death. TAS266 triggers sustained tumor regression in xenograft models and also elicits immunogenic responses including antibody binding. TAS266 exhibits superior anti-tumor efficacy compared with traditional DR5-targeting strategies. TAS266 can be used in research related to pancreatic cancer and advanced solid tumors.

Species: Human

TNF Receptor  
Inflammation or Immune System Disease   Pancreatic Cancer  
/
HY-W726767 DO2A
DO2Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO2A can be used for conjugation of peptides and radionuclides.
Biochemical Assay Reagents  
Cancer  
/
HY-P991634 IBI-325
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.

Species: Human

CD73   TNF Receptor   Interleukin Related   IFNAR  
Cancer   Inflammation or Immune System Disease  
/
HY-168947A Green Fluorescent PLGA nanoparticles, 200nm
Green Fluorescent PLGA nanoparticles, 200nm is a PLGA nanoparticle labeled with a green fluorescent dye and is commonly used in imaging and diagnostic applications.
Fluorescent Dye  
/
HY-N15990 4ME 16:0 Diether PE
4ME 16:0 Diether PE is a phospholipid that can be used to prepare lipid nanoparticles for drug delivery.

Source: Methanosarcina barkeri

Biochemical Assay Reagents  
/
HY-145941 AETA
AETA (2-Acryloxyethyltrimethylammonium chloride) can be used for the synthesis of hydrophilic polymers and hydrogels. Hydrogels are used for membranes, catheters, contact lenses, and drug delivery systems.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-131328S Pirtobrutinib-13C,d3
Pirtobrutinib-13C,d3 (LOXO-305-13C,d3) is the deuterated, 13C-labeled Pirtobrutinib (HY-131328). Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM.
Isotope-Labeled Compounds   Btk  
Non-Hodgkin Lymphoma  
/
HY-P11186 CALNN
CALNN is a pentapeptide that can be used as a ligand to stabilise and functionalise gold nanoparticles in drug delivery systems.
Others  
Cancer  
/
HY-P6299 MAX8
MAX8 is a synthetic β-hairpin peptide that folds rapidly and self-assembles into a β-sheet-rich fibrous hydrogel network via non-covalent crosslinking. MAX8 hydrogel exhibits excellent shear-thinning and self-healing properties, enabling precise delivery via syringe and maintaining local retention after implantation. MAX8 hydrogel can uniformly encapsulate cells while preserving their viability and morphology, and protect growth factors (e.g., NGF) and chemotherapeutic drugs from degradation. MAX8 is applicable for spinal cord injury repair, medulloblastoma treatment, and three-dimensional high-throughput drug screening.
Biochemical Assay Reagents  
Nervous System Injury   Glioblastoma  
/
HY-155227S ALK/EGFR-IN-1-d5
ALK/EGFR-IN-1-d5 (Compound (-)-9a) is a deuterated dual-target inhibitor of EGFR and ALK, with an IC50 of 1.08 nM for EGFR and an IC50 of 2.395 nM for ALK. ALK/EGFR-IN-1-d5 inhibits the phosphorylated proteins in the EGFR, ALK, and BRK signaling pathways, blocking the cell cycle, leading to a reduction in mitochondrial membrane potential and cell apoptosis (Apoptosis). ALK/EGFR-IN-1-d5 also significantly inhibits tumor growth in animal models and demonstrates good safety. ALK/EGFR-IN-1-d5 holds promise for research in the field of cancer treatment
Isotope-Labeled Compounds   EGFR   Anaplastic lymphoma kinase (ALK)   BRK   Apoptosis   Mitochondrial Metabolism  
Cancer  
/
HY-20457G TL8-506 (GMP)
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.
Toll-like Receptor (TLR)   Bacterial   Interleukin Related  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P991384 DX-2240
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors).

Species: Human

Tie  
Cancer  
/
HY-B0380S2 Trimebutine-d3 hydrochloride
Trimebutine-d3 hydrochloride is deuterium labeled Trimebutine hydrochloride. Trimebutine hydrochloride is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine hydrochloride inhibits L-type Ca2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine hydrochloride also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine hydrochloride also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine hydrochloride also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS).
Apoptosis   Isotope-Labeled Compounds   Calcium Channel   ERK   Akt   Toll-like Receptor (TLR)   IRAK   NF-κB   Opioid Receptor   Potassium Channel   JNK  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-134418A NOTA trihydrochloride
NOTA (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTA (trihydrochloride) can be used for conjugation of peptides and radionuclides.
Biochemical Assay Reagents   Radionuclide-Drug Conjugates (RDCs)  
/
HY-168947 Green Fluorescent PLGA nanoparticles, 100nm
Green Fluorescent PLGA nanoparticles, 100nm is a PLGA nanoparticle labeled with a green fluorescent dye and is commonly used in imaging and diagnostic applications.
Fluorescent Dye  
/
HY-P991476 MDX-220
MDX-220 is a human monoclonal antibody (mAb) targeting FcRn. MDX-220 has anti-tumor activity.

Species: Human

Fc Receptor (FcR)  
Cancer  
/
HY-D2004 ATTO 488 streptavidin
ATTO 488 streptavidin is a fluorescent reagent that specifically targets and binds to biotin (biotin), formed by the conjugation of ATTO 488 with streptavidin (HY-P3152). ATTO 488 streptavidin enables visualization of the activity of streptavidin immobilized on the surface of polymeric nanoparticles, or acts as a fluorescent probe to detect the selective binding and internalization process of anti-HB-EGF/NA with cells expressing HB-EGF (with no such effect on cells that do not express this receptor). ATTO 488 streptavidin effectively verifies the function of streptavidin conjugated to the surface of nanoparticles and is suitable for research related to atherosclerotic cardiovascular diseases.
Fluorescent Dye  
Atherosclerosis and Inflammation  
/
HY-P11059 MC38 SLP Reps1
MC38 SLP Reps1 is a peptide neoantigen generated by mutation of the MC38 colon cancer cell line and can be used for the synthesis of nanoparticle vaccines.
Others  
/
HY-B0380S1 Trimebutine-d5 fumarate
Trimebutine-d5 fumarate is deuterium labeled Trimebutine fumarate. Trimebutine fumarate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine fumarate inhibits L-type Ca2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine fumarate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine fumarate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine fumarate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS).
Apoptosis   Isotope-Labeled Compounds   Calcium Channel   ERK   Akt   Toll-like Receptor (TLR)   IRAK   NF-κB   Opioid Receptor   Potassium Channel   JNK  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P10715 Fmoc-KCRGDK
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
Others  
Inflammation or Immune System Disease  
/
HY-D2334 AlF-NOTA-c-d-VAP
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo.
Radionuclide-Drug Conjugates (RDCs)   HSP  
/
HY-B0180S1 Imiquimod-d9
Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Isotope-Labeled Compounds   Toll-like Receptor (TLR)   Autophagy   SARS-CoV   HSV  
Infection   Inflammation or Immune System Disease  
/
HY-B0180S Imiquimod-d6
Imiquimod-d6 is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Toll-like Receptor (TLR)   Autophagy   SARS-CoV   HSV  
Infection   Inflammation or Immune System Disease  
/
HY-172168A Orange Fluorescent PLGA nanoparticles, 200nm
Orange Fluorescent PLGA nanoparticles, 200nm a nanoparticle made from the polymer PLGA and labeled with an orange fluorescent dye. Orange Fluorescent PLGA nanoparticles, 200nm can be used for drug delivery and for tracing.
Fluorescent Dye  
/
HY-P5033 Cyclo(Gly-His)
Cyclo(Gly-His) is a liposome-encapsulated cyclic dipeptide with antimicrobial and anticancer activity. Cyclo(Gly-His) has cytotoxicity for HeLa and MCF-7 cell with IC50 values of 1.699 mM and 0.358 mM, respectively. Cyclo(Gly-His) can be used for the research of drug delivery systems.
Bacterial  
Cancer  
/
HY-D0356 Eriochrome Black A
Eriochrome Black A is an azo dye that can be removed from water by an adsorbent made of magnetic NiFe2O4 nanoparticles.
Fluorescent Dye  
/
HY-172168B Orange Fluorescent PLGA nanoparticles, 500nm
Orange Fluorescent PLGA nanoparticles, 500nm a nanoparticle made from the polymer PLGA and labeled with an orange fluorescent dye. Orange Fluorescent PLGA nanoparticles, 500nm can be used for drug delivery and for tracing.
Fluorescent Dye  
/
HY-145782 Witepsol
Witepsol is a selective lipid-based vehicle for use in drug delivery systems.
Liposome  
Metabolic or Endocrine Disease  
/
HY-138170GL ALC-0315 (GMP Like)
ALC-0315 (GMP Like) is ALC-0315 (HY-138170) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. ALC-0315 is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. ALC-0315 can be used to form lipid nanoparticle (LNP) delivery vehicles. Lipid-Nanoparticles have been used in the research of mRNA COVID-19 vaccine.
Liposome   SARS-CoV  
Infection  
/
HY-W040193S1 DSPC-d74
DSPC-d74 (1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d74) is the deuterium labeled DSPC (HY-W040193). DSPC is a cylindrical-shaped lipid. 1,2-Distearoyl-sn-glycero-3-phosphorylcholine is used to synthesize liposomes, and is the lipid component in the lipid nanoparticle (LNP) system.
Isotope-Labeled Compounds   Liposome  
/
HY-172168 Orange Fluorescent PLGA nanoparticles, 100nm
Orange Fluorescent PLGA nanoparticles, 100nm a nanoparticle made from the polymer PLGA and labeled with an orange fluorescent dye. Orange Fluorescent PLGA nanoparticles, 100nm can be used for drug delivery and for tracing.
Fluorescent Dye  
/
HY-13762S Tesmilifene-d4
Tesmilifene-d4 is the deuterium labeled Tesmilifene (HY-13762). Tesmilifene is an antihistamine agent and a chemical sensitizer. Tesmilifene targets cytochrome P450, exhibits hormonal effects on DNA synthesis in MCF-7 cells, and stimulates the tumor growth in mouse/rat models. Tesmilifene overcomes multidrug resistance.
Isotope-Labeled Compounds   Cytochrome P450  
/
HY-111582G BBIQ (GMP)
BBIQ (GMP) is BBIQ (HY-111582) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BBIQ is a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of  59.1 nM. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-N7131R Coumarin 6 (Standard)
Coumarin 6 (Standard) is the analytical standard of Coumarin 6 (HY-N7131). This product is intended for research and analytical applications. Coumarin 6, a fluorescent dye, is used as a fluorescent probe in a microparticle drug delivery system to conduct in vivo tracking, cell uptake, and transport mechanism studies of drug delivery systems (λexc=450 nm, λem=505 nm).
Fluorescent Dye   Reference Standards  
/
HY-N16029 C18:0 Fuc-GM1 Ceramide (d18:1/18:0)
C18:0 Fuc-GM1 Ceramide (d18:1/18:0) is a ganglioside that can be used to synthesize lipid nanoparticles for drug delivery.
Biochemical Assay Reagents  
Cancer  
/
HY-N15825 C24:1 GB3 Ceramide (d18:1/24:1)
C24:1 GB3 Ceramide (d18:1/24:1) is a globoside that can be used to prepare lipid nanoparticles for drug delivery.
Biochemical Assay Reagents  
/
HY-32350S1 Ercalcitriol-d3
Ercalcitriol-d3 (1α,25-Dihydroxy Vitamin D2-d3) is the deuterium labeled Ercalcitriol (HY-32350). Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
Isotope-Labeled Compounds   VD/VDR   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-N15844 C24:1 GM3 Ceramide (d18:1/24:1)
C24:1 GM3 Ceramide (d18:1/24:1) is a globoside that can be used to prepare lipid nanoparticles for drug delivery.
Biochemical Assay Reagents  
/
HY-172174B Red Fluorescent PLGA nanoparticles, 500nm
Red Fluorescent PLGA nanoparticles, 500nm is a nanoparticle made from the polymer PLGA and labeled with a red fluorescent dye. Red Fluorescent PLGA nanoparticles, 500nm can be used for drug delivery and for tracing.
Fluorescent Dye  
/
HY-B0180S2 Imiquimod-d7
Imiquimod-d7 (R 837-d7) is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
Isotope-Labeled Compounds   HSV   Autophagy   Toll-like Receptor (TLR)   SARS-CoV  
Infection   Inflammation or Immune System Disease  
/
HY-P991330 BMS-986179
BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research.

Species: Human

CD73  
Cancer  
/
HY-172174A Red Fluorescent PLGA nanoparticles, 200nm
Red Fluorescent PLGA nanoparticles, 200nm is a nanoparticle made from the polymer PLGA and labeled with a red fluorescent dye. Red Fluorescent PLGA nanoparticles, 200nm can be used for drug delivery and for tracing.
Fluorescent Dye  
/
HY-N16510 Cinnabarone
Cinnabarone is a biflavonoid that can be isolated from dragon's blood of Dracaena cinnabari. Cinnabarone is a reducing and stabilizing agent which can be used for formation of silver nanoparticles.
Others  
/
HY-W050154R Kojic acid (Standard)
Kojic acid (Standard) is the analytical standard of Kojic acid. This product is intended for research and analytical applications. Kojic acid is a substance produced by Aspergillus oryzae, with various biological activities including antitumor, insecticidal, antibacterial, antioxidant, and radioprotective effects. Kojic acid exhibits tyrosinase inhibition activity by capturing copper ions that bind to the active site of tyrosinase, preventing its activation. Tyrosinase is a key enzyme in the biosynthesis of melanin, so kojic acid can block melanin production. Additionally, kojic acid shows potential inhibition of NF-κB activity in human keratinocytes, which may also be related to the anti-melanogenic effect induced by kojic acid. Kojic acid is effective when administered orally and can also be absorbed transdermally. Nano-carrier systems prepared with kojic acid demonstrate effective delivery of anticancer drugs. Kojic acid holds promise for research in cancer, infectious diseases, and skin whitening among other fields.
Reference Standards   Parasite   Tyrosinase   NF-κB   CDK  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P9994 Pertuzumab zuvotolimod
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research.
Antibody-Drug Conjugates (ADCs)   EGFR   Toll-like Receptor (TLR)  
Cancer   Inflammation or Immune System Disease  
/
HY-144002 RIBI-529
RIBI-529 (RC-529) is a fully synthetic, low-toxicity TLR4 agonist vaccine adjuvant. RIBI-529 upregulates cell surface co-stimulatory molecules, receptors, cytokines and chemokines, and activates the innate immune system. RIBI-529 enhances short-term CD4+ T cell clonal expansion, division, and ex vivo survival under growth factor withdrawal conditions. RIBI-529 enhances humoral and cell-mediated adaptive immune responses, induces non-specific resistance against viral and bacterial pathogens, and skews responses toward a Th1 type, accompanied by Th2 responses.
Toll-like Receptor (TLR)   Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P99004 hMC1R agonist 1
hMC1R agonist 1 is a selective hMC1R agonist. hMC1R agonist 1 activates adenylate cyclase to induce intracellular cAMP accumulation. hMC1R agonist 1 can be used for the research of immune-inflammatory disorders.
Melanocortin Receptor  
Inflammation or Immune System Disease  
/
HY-134541G SM-102 (GMP)
SM-102 (GMP) is SM-102 (HY-134541) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SM-102 is an amino cationic lipid useful in the formation of lipid nanoparticles (LNPs). SM-102 has higher transfection efficiency. SM-102 plays an important role in the effectiveness of lipid nanoparticles (LNPs) in delivering mRNA therapeutics and vaccines.
Liposome  
Infection  
/
HY-P991126 Ciltistotug
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P991125 Cenzestotug
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P10699 MAX1
MAX1 is a synthetic β-hairpin peptide that folds rapidly and self-assembles into a β-sheet-rich fibrous hydrogel network via non-covalent crosslinking. MAX1 hydrogel exhibits excellent shear-thinning and self-healing properties, enabling precise delivery via syringe and maintaining local retention after implantation. MAX1 hydrogel can uniformly encapsulate cells while preserving their viability and morphology, and protect growth factors (e.g., NGF) and chemotherapeutic drugs from degradation. MAX1 is applicable for spinal cord injury repair, medulloblastoma treatment, and three-dimensional high-throughput drug screening.
Biochemical Assay Reagents  
Nervous System Injury   Glioblastoma  
/
HY-P11294 KLVVVGADGVGKSALTI
KLVVVGADGVGKSALTI is a KRAS G12D targeting peptide that can be used in tumor research.
Ras  
Cancer  
/
HY-NP134 Flagellin from S. typhimurium
Flagellin from S. typhimurium is a potent TLR5 agonist. Flagellin from S. typhimurium activates immune cells and inhibits the activity of melanoma cells. Flagellin from S. typhimurium activates the NF-κB pathway dependent on the TLR5/MyD88/TRAF6 signaling axis in cells. Flagellin from S. typhimurium induces a proinflammatory response in the primary chicken hepatocyte-nonparenchymal cell co-culture system by promoting IL-8 production, inhibiting IL-10 production, and increasing the IFN-γ/IL-10 ratio. Flagellin from S. typhimurium can be used for research on melanoma and inflammatory diseases.
Toll-like Receptor (TLR)   MyD88   NF-κB   Interleukin Related   IFNAR  
Inflammation or Immune System Disease   Melanoma  
/
HY-P4091 LSD
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics.
Biochemical Assay Reagents  
Cancer  
/
HY-P992112 Eliroptamig
Eliroptamig is a multispecific antibody targeting albumin, folate receptor α (FOLR1) and cluster of differentiation 3 (CD3). Eliroptamig extends its half-life by binding to albumin, while targeting FOLR1 on tumor cells and activating T cells to achieve precise tumor killing.

Species: Human

Folate Receptor (FR)   CD3  
Cancer  
/
HY-78985S Benzene-1,3,5-tricarboxylic acid-d3
Benzene-1,3,5-tricarboxylic acid-d3 (Trimesic acid-d3) is the deuterium labeled Benzene-1,3,5-tricarboxylic acid (HY-78985). Benzene-1,3,5-tricarboxylic acid (Trimesic acid) is a rigid planar small-molecule scaffold and crosslinker. Benzene-1,3,5-tricarboxylic acid induces bicyclic peptides to adopt a planar conformation, so as to maximize surface area and bind to the flat protein surfaces involved in protein-protein interactions. Benzene-1,3,5-tricarboxylic acid forms ionic crosslinks, hydrogen bonds and π-π bonds with chitosan, thereby constructing a hydrogel network. Benzene-1,3,5-tricarboxylic acid endows chitosan hydrogel systems with specific mechanical properties, enabling sustained release of cancer therapeutic drugs including 5-Fluorouracil (HY-90006).
Isotope-Labeled Compounds   Biochemical Assay Reagents   MOFs  
/
HY-W040193S3 DSPC-d83
DSPC-d83 (1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d83) is the deuterium labeled DSPC (HY-W040193). DSPC is a cylindrical-shaped lipid. 1,2-Distearoyl-sn-glycero-3-phosphorylcholine is used to synthesize liposomes, and is the lipid component in the lipid nanoparticle (LNP) system.
Isotope-Labeled Compounds   Liposome  
/
HY-W040193S4 DSPC-d4
DSPC-d4 (1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d4) is the deuterium labeled DSPC (HY-W040193). DSPC is a cylindrical-shaped lipid. 1,2-Distearoyl-sn-glycero-3-phosphorylcholine is used to synthesize liposomes, and is the lipid component in the lipid nanoparticle (LNP) system.
Isotope-Labeled Compounds   Liposome  
/
HY-P10217 PD-1/PD-L1-IN-42
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P99057A Varlilumab (anti-CD27)
Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27 monoclonal antibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors.

Species: Human

TNF Receptor   Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-P99035 Naptumomab
Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma.

Species: Human

Others  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Luminal Breast Cancer   Triple-Negative Breast Cancer  
/
HY-112764GL mPEG2000-DMG (GMP Like)
mPEG2000-DMG (GMP Like) is mPEG2000-DMG (HY-112764) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. mPEG2000-DMG is used for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. mPEG2000-DMG is also used for the lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles.
Liposome  
Metabolic or Endocrine Disease  
/
HY-P10679 GPLGLAGGWGERDGS
GPLGLAGGWGERDGS is a peptide with MMP enzyme responsiveness and tumor targeting function, which can be used to monitor enzyme-guided nanoparticle assembly in tumors.
MMP  
/
HY-10227S Bortezomib-d8
Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
Isotope-Labeled Compounds   Proteasome   NF-κB   Apoptosis   Autophagy   TREM receptor  
Cancer  
/
HY-W145481A D-Galacto-D-mannan
D-Galacto-D-mannan (Carob galactomannan) is an orally active Dectin-2 agonist. D-Galacto-D-mannan exerts antioxidant activity against hydroxyl radical generation. D-Galacto-D-mannan activates Dectin-2 to trigger downstream signaling pathways, promote the expression of immunoregulatory molecules, coordinate innate and adaptive immune responses, and inhibit excessive inflammatory responses by upregulating the expression of Sirtuin 1. When used as a vaccine adjuvant, D-Galacto-D-mannan induces cellular and humoral immune responses, promotes IFNγ secretion, increases antibody levels and virus neutralization titers, and elevates the levels of immunoglobulin G and A. D-Galacto-D-mannan can serve as an adjuvant for foot-and-mouth disease vaccines, enhance the vaccine-mediated ability of hosts to defend against viral infection in mice, and reduce local side effects at the inoculation site in pigs. D-Galacto-D-mannan can be used in the research of inflammatory and immune diseases, such as foot-and-mouth disease.
C-type Lectin-like Receptors (CTLRs)   Sirtuin  
Inflammation or Immune System Disease  
/
HY-P99382A Vopratelimab (Mouse IgG2a)
Vopratelimab (Mouse IgG2a) is a agonist monoclonal antibody that selectively targets Inducible CO-Stimulator of T cells (ICOS). The variable region of Vopratelimab (Mouse IgG2a) is consistent with that of Vopratelimab (HY-P99382), while the constant region is of Mouse IgG2a sequence. Vopratelimab (Mouse IgG2a) has antitumor immune response and enhances combinatorial efficacy with anti-PD-1 (HY-P9902A) therapy.

Species: Human

Others  
Cancer  
/
HY-P991455 PTX-35
PTX-35 is a costimulatory agonist antibody targeting TNFRSF25 as well as an immune activator that selectively regulates activated CD8+ T cells. PTX-35 enhances the expansion, survival and effector functions of T cells, while reducing the inhibitory activity of regulatory T cells and impairing their stability. PTX-35 exhibits anti-tumor activity, effectively delaying tumor progression and prolonging survival. PTX-35 has a synergistic effect with anti-OX40 agonist antibodies. PTX-35 can be widely used in research on related diseases such as colon cancer and melanoma.

Species: Human

TNF Receptor  
Colorectal Cancer   Cancer Immunology   Immunotherapy for Melanoma  
/
HY-P10502 L57
L57 is a low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 exhibits high affinity for LRP1, with an EC50 of 45 nM. L57 possesses blood-brain barrier (BBB) permeability and plasma stability. L57 can serve as a carrier for central nervous system drug delivery.
LDLR  
CNS Infection  
/
HY-138269A Barzuxetan hydrochloride
Barzuxetan (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Barzuxetan (hydrochloride) can be used for conjugation of peptides and radionuclides.
Biochemical Assay Reagents  
/
HY-D2439 RGD-PEG-Cy3
RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting.
Fluorescent Dye  
/
HY-114364S UDP-α-D-Galactose-13C disodium
UDP-α-D-Galactose-13C disodium is the 13C labeled UDP-α-D-Galactose disodium. UDP-Galactose disodium is a monosaccharide and a key glycosyl donor molecule in cells that participates in nucleotide sugar metabolism. UDP-Galactose disodium is the natural agonist of the P2Y14 receptor coupled to Gi proteins in the immune system (IC50 = 0.67 μM, hP2Y14). UDP-Galactose disodium can be used to study cell signal transduction and substance metabolism.
Isotope-Labeled Compounds  
/
HY-P10862A AH-D peptide TFA
AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-W088413 DOTA-amide
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.
Biochemical Assay Reagents  
/
HY-P11205A Cys-PKHB1 TFA
Cys-PKHB1 (Cys-txCD47) TFA is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
CD47   Reactive Oxygen Species (ROS)   Thrombopoietin Receptor  
Inflammation or Immune System Disease  
/
HY-P3486 GADGVGKSAL
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P10862 AH-D peptide
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with
IC50
values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1+ exosomes, reducing intratumoral immunosuppressive cells (regulatory T cells, myeloid-derived suppressor cells), and enhancing T cell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-P3487 GAGGVGKSA
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-113008AS cis-Urocanic acid-13C3
cis-Urocanic acid-13C3 is the 13C-labeled cis-Urocanic acid. cis-Urocanic acid is a 5-HT2A receptor agonist. cis-Urocanic acid binds to 5-HT receptor with relatively high affinity (Kd=4.6 nM). cis-Urocanic acid is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.
Isotope-Labeled Compounds   5-HT Receptor  
Inflammation or Immune System Disease  
/
HY-N16040 DMG-pSar25
DMG-pSar25 is a double lipid-tailed polysarcosine lipid with 25 sarcosine moieties, serving as a PEG lipid substitute in lipid nanoparticle formulations for mRNA delivery. DMG-pSar25 supports mRNA delivery in lipid nanoparticle formulations.
Liposome  
/
HY-P99834 Crefmirlimab
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.

Species: Human

Transmembrane Glycoprotein  
Lung Cancer  
/
HY-134541GL SM-102 (GMP Like)
SM-102 (GMP Like) is SM-102 (HY-134541) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SM-102 is an amino cationic lipid useful in the formation of lipid nanoparticles (LNPs). SM-102 has higher transfection efficiency. SM-102 plays an important role in the effectiveness of lipid nanoparticles (LNPs) in delivering mRNA therapeutics and vaccines.
Liposome  
Infection  
/
HY-126304R β-Glycerophosphate disodium salt hydrate (Standard)
β-Glycerophosphate disodium salt hydrate (Standard) is the analytical standard of β-Glycerophosphate disodium salt hydrate (HY-126304). This product is intended for research and analytical applications. β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells.
Reference Standards   ERK   Endogenous Metabolite   Phosphatase  
/
HY-P1828A EGFRvIII peptide (PEPvIII) TFA
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy.
EGFR  
Cancer  
/
HY-P10501A FRα-targeting peptide C7 TFA
FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment.
Antifolate  
Cancer  
/
HY-W782078 Butyne-DOTA
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.
Biochemical Assay Reagents   Radionuclide-Drug Conjugates (RDCs)  
/
HY-P10424 OPBP-1
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P3488 GADGVGKSA
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P10792 HER2-targeted peptide H6F
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies.
EGFR  
/
HY-40118 Boc-Pro-OMe
Boc-Pro-OMe (Boc-L-proline methyl ester) is a lipid compound that can be used for liposome preparation. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble loads can be captured in the internal aqueous space of liposomes, while lipophilic loads can be distributed into the lipid bilayer and become part of the lipid bilayer. Especially for the delivery of antisense oligonucleotides, it can overcome the problems of inefficient cellular uptake and rapid loss in the body.
Liposome  
/
HY-172174 Red Fluorescent PLGA nanoparticles, 100nm
Red Fluorescent PLGA nanoparticles, 100nm is a nanoparticle made from the polymer PLGA and labeled with a red fluorescent dye. Red Fluorescent PLGA nanoparticles, 100nm can be used for drug delivery and for tracing.
Fluorescent Dye  
/
HY-141629S2 N-Palmitoyl-D-sphingomyelin-d9
N-Palmitoyl-D-sphingomyelin-d9 (Sphingomyelin 16:0-d9) is deuterium labeled N-Palmitoyl-D-sphingomyelin. N-Palmitoyl-D-sphingomyelin (Sphingomyelin 16:0) (Compound SM-03) can be used for the synthesis of lipid nanoparticles.
Isotope-Labeled Compounds   Endogenous Metabolite   Liposome  
/
HY-P2532 Integrin Binding Peptide
Integrin Binding Peptide is derived by fibronectin. Integrin Binding Peptide can be used for PEG hydrogel preparation.
Integrin  
/
HY-DY1091 Calcein (solution)
Calcein (solution) (Fluorexon (solution)) is a fluorescent dye and self-quenching probe, used as an indicator of lipid vesicle leakage, and also as a complexometric indicator for titration of calcium ions with EDTA, and for fluorometric determination of calcium. Calcein cannot directly cross the intact cell membrane of a living cell, unlike Calcein-AM (HY-D0041) which is cell-permeable. Calcein can also be used as a model drug for evaluating efficiency and bioavailability of drug delivery systems.
Solvent and concentration: DMSO: 2 mM
The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.
Fluorescent Dye  
/
HY-P5533 CRT
CRT, an iron peptide mimic, can bind to apo-transferrin (apo-Tf). CRT can be used to modify nanoparticles, and enhances drug delivery efficiency.
Biochemical Assay Reagents  
Cancer  
/
HY-B1620I Polyvinylpyrrolidone K120
Polyvinylpyrrolidone K120 is a multifunctional synthetic polymer with excellent adhesiveness and thickening properties. Polyvinylpyrrolidone K120 is a versatile excipient for both conventional formulations and novel controlled or targeted delivery systems. Polyvinylpyrrolidone K120 can be used to prepare drug-loaded hydrogel patches.
Environmental Pollutants   Biochemical Assay Reagents  
/
HY-N9459 2-Amino-2-deoxyglucose hydrochloride
2-Amino-2-deoxyglucose hydrochloride (D-Glucosamine Hydrochloride) is a glucose analog that is specifically recognized and transported by the cell membrane GLUT1. 2-Amino-2-deoxyglucose hydrochloride acts as a tumor-targeting ligand and a guiding molecule for the synthesis of prodrug conjugates, thus delivering drugs precisely to tumor cells. 2-Amino-2-deoxyglucose hydrochloride is applicable to diagnostic imaging and therapeutic efficacy monitoring of solid tumors and various cancers (e.g., breast cancer, glioblastoma). 2-Amino-2-deoxyglucose hydrochloride also helps bacteria resist lysozyme digestion by integrating into the non-N-acetylated residues of Streptococcus pneumoniae peptidoglycan. 2-Amino-2-deoxyglucose hydrochloride is used in studies on tumor metabolism and the exploration of bacterial drug resistance mechanisms.

Source: Shrimp, crab and other crustaceans

GLUT  
Breast Cancer   Bacterial Infection   Glioblastoma  
/
HY-171544 AGS-16C3F
AGS-16C3F is an antibody-drug conjugate (ADC) targeting ENPP3. AGS-16C3F is composed of ENPP3-targeting Anti-ENPP3/CD203c Antibody (HY-P990315) linked to Monomethyl auristatin F (HY-15579) via a linker. AGS-16C3F has anti-tumor activity and can be used in the study of metastatic renal cell carcinoma (mRCC).
Antibody-Drug Conjugates (ADCs)   Phosphodiesterase (PDE)  
/
HY-W110542D Poly(ethylene glycol) diacrylate (MW 1000)
Poly(ethylene glycol) diacrylate (PEGDA) (MW 1000) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine.
Biochemical Assay Reagents  
/
HY-P11281A GYGGGP(GPP)5GFOGER(GPP)5GPC TFA
GYGGGP(GPP)5GFOGER(GPP)5GPC TFA is a type I collagen mimic that can bind to integrins and modify hydrogels.
Others  
Inflammation or Immune System Disease  
/
HY-166990A Methoxypolyethylene glycol maleimide 10000
Methoxypolyethylene glycol maleimide 10000 (MeO-PEG10000-Mal) can serve as a PEGylation reagent for bioconjugation, playing a role in protein modification and drug delivery systems.
Biochemical Assay Reagents  
/
HY-D1005A2 Poloxamer 105 (L35)
Poloxamer 105 L35 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 1900 Da. Poloxamer 105 L35 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering.
Environmental Pollutants   Biochemical Assay Reagents  
/
HY-166990B Methoxypolyethylene glycol maleimide 2000
Methoxypolyethylene glycol maleimide 2000 (MeO-PEG2000-Mal) can serve as a PEGylation reagent for bioconjugation, playing a role in protein modification and drug delivery systems.
Biochemical Assay Reagents  
/
HY-166990 Methoxypolyethylene glycol maleimide 5000
Methoxypolyethylene glycol maleimide 5000 (MeO-PEG-Mal) can serve as a PEGylation reagent for bioconjugation, playing a role in protein modification and drug delivery systems.
Biochemical Assay Reagents  
/
HY-N7434S1 N-Nitrosodiethylamine-d10
N-Nitrosodiethylamine-d10 is the deuterium labeled N-Nitrosodiethylamine. N-Nitrosodiethylamine (Diethylnitrosamine) is a potent hepatocarcinogenic dialkylnitrosoamine. N-Nitrosodiethylamine is mainly present in tobacco smoke, water, cheddar cheese, cured, fried meals and many alcoholic beverages. N-Nitrosodiethylamine is responsible for the changes in the nuclear enzymes associated with DNA repair/replication. N-Nitrosodiethylamine results in various tumors in all animal species. The main target organs are the nasal cavity, trachea, lung, esophagus and liver.
DNA/RNA Synthesis  
Cancer  
/
HY-W678394 DOTA-Thiol
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.
Biochemical Assay Reagents  
/
HY-P11058 OVA(250-264)
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
MHC  
/
HY-W110542N Poly(ethylene glycol) diacrylate (MW 250),MEHQ as inhibitor
Poly(ethylene glycol) diacrylate (PEGDA) (MW 250), MEHQ as inhibitor is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 250), MEHQ as inhibitor can be used to construct optical cross-linked hydrogel implants.
Biochemical Assay Reagents  
/
HY-W127640 Phosphocholine chloride disodium
Phosphocholine Chloride Sodium Salt is an organic compound containing phosphate, choline and chloride ions. It is commonly used to prepare cell membranes and liposomes for drug delivery systems. Phosphocholine Chloride Sodium Salt has various applications in the pharmaceutical industry, especially as a stabilizer and surfactant. In addition, it is used as an emulsifier and conditioning agent in the manufacture of cosmetic and personal care products.
Biochemical Assay Reagents  
/
HY-159114 Whole Glucan Particles
Whole Glucan Particles is a Dectin-1a agonist. Whole Glucan Particles activates the innate immune system to improve the function of macrophages, monocytes and other immune cells.
C-type Lectin-like Receptors (CTLRs)   Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-W040193S DSPC-d70
DSPC-d70 (1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d70) is the deuterium labeled DSPC (HY-W040193). DSPC is a cylindrical-shaped lipid. 1,2-Distearoyl-sn-glycero-3-phosphorylcholine is used to synthesize liposomes, and is the lipid component in the lipid nanoparticle (LNP) system.
Isotope-Labeled Compounds   Liposome  
/
HY-W110542P Poly(ethylene glycol) diacrylate (MW 4000), MEHQ as inhibitor
Poly(ethylene glycol) diacrylate (PEGDA) (MW 4000), MEHQ as inhibitor is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 4000), MEHQ as inhibitor can be used to construct enzyme-responsive hydrogel drug delivery system.
Biochemical Assay Reagents  
/
HY-121447 Heneicosanoic acid
Heneicosanoic acid is an odd-chain saturated fatty acid widely present in human milk, fish, seeds, and cerebrosides in the cell membranes of the nervous system. Heneicosanoic acid can form Langmuir monolayers and is often used as a model to study lipid self-assembly and disassembly processes in biological membranes and drug delivery systems. In the low-temperature L'2 and CS crystalline phases, Heneicosanoic acid undergoes local oscillations, which in turn drive the spontaneous formation and expulsion of micelles and vesicles.
Endogenous Metabolite  
Lipid Metabolism  
/
HY-W763806 Zein
Zein is a plant protein‐based polymer, can be used to prepare nanofibrous mats through electrospun. Zein has good cell compatibility and easy fabrication ability, and can be used in drug delivery systems.
Environmental Pollutants   Biochemical Assay Reagents  
/
HY-P99382 Vopratelimab
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response.

Species: Human

Others  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-P99057 Varlilumab
Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors.

Species: Human

TNF Receptor   Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-P1771A OVA G4 peptide TFA
OVA G4 peptide TFA is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P10294 Oligopeptide P11-4
Oligopeptide P11-4 is an α-peptide that can be self-assembled into β-sheet amyloids with a hydrogel appearance at low pH. Oligopeptide P11-4 can be used in biomimetic mineralization, enamel regeneration and oral care agent.
Amyloid-β  
/
HY-W763582B GelMA, 90% methacrylation
GelMA (Gelatin Methacryloyl), 90% methacrylation, is a derivative obtained by the reaction of Methacrylic anhydride (MA) (HY-W017330) and gelatin. GelMA exhibits excellent biocompatibility, biodegradability, and moldability. GelMA can be photocrosslinked into hydrogels and can be used for research in regeneration of tissues, such as skin, tendon, bone, cartilage, blood vessel, and cardiovascular system. GelMA hydrogel also can be used for research on drug delivery, organ-on-a-chip, and biosensing.
Biochemical Assay Reagents  
/
HY-113003 H-γ-Glu-Gln-OH
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy.
Others  
Cancer  
/
HY-D1716 S0456
S0456 is a raw material that plays a crucial role in the construction of the folate receptor-targeted near-infrared dye OTL 38 (HY-139579). S0456 is connected to the modified folic acid to form OTL 38, endowing OTL 38 with good optical properties, high affinity, and specificity. S0456 can be used in the research of tumor optical imaging agents.
Fluorescent Dye   Drug Intermediate  
/
HY-P10131 3BP-3940
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases.
Radionuclide-Drug Conjugates (RDCs)   FAP  
Cancer  
/
HY-W250313 Polylactic acid
Polylactic acid (PLA) is a biodegradable and biocompatible polymer widely used as a carrier for drug delivery systems and a structural material for tissue engineering and medical implants. Polylactic acid acts as a controlled release matrix through the hydrolysis mechanism of ester bonds, gradually releasing the encapsulated drug and metabolizing to non-toxic lactic acid. Polylactic acid has adjustable degradation rate, mechanical properties and the ability to composite with other polymers, and can be used in local or systemic drug delivery, orthopedic fixation devices and 3D printed bone regeneration scaffolds.
Biochemical Assay Reagents  
Cancer  
/
HY-N2424 Flavone
Flavone is an anti-tumor compound that targets cell cycle regulatory proteins (such as cyclin B1) and apoptosis-related factors (such as p21waf1, PIG3). Flavone selectively induces mitochondrial-mediated apoptosis pathways in tumor cells, inhibits cyclin B1 protein expression, upregulates p21waf1, and activates p63/p73 proteins. Flavone has immunomodulatory functions that enhance natural killer cell (NK cell) activity and lymphocyte proliferation. Flavone is used in cancer research, especially for its inhibitory potential in solid tumor models such as esophageal cancer and liver cancer.
CDK   Caspase   Apoptosis  
Breast Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
/
HY-107202GL Polyinosinic-polycytidylic acid (GMP Like)
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Inflammation or Immune System Disease  
/
HY-W006371 (2-Aminoethyl)phosphonic acid
(2-Aminoethyl)phosphonic acid is an endogenous metabolite and amino acid analog. (2-Aminoethyl)phosphonic acid can be used for the synthesis of biological macromolecules and the preparation of hydrogels.
Endogenous Metabolite   Drug Intermediate  
Metabolic or Endocrine Disease  
/
HY-W019682 Fmoc-FF
Fmoc-FF is a building block. Fmoc-FF-prepared hydrogels and nanogels selectively deliver Dexamethasone (HY-14648) to leukemia cells.
Biochemical Assay Reagents  
Leukemia/Lymphoma/Myeloma  
/
HY-N6613 Polygalacturonic acid
Polygalacturonic acid (Galacturonic acid polymer) is transparent colloid, is a major component of the cell wall. Polygalacturonic acid can be used to prepare silver nanoparticles (AgNPs), as an antioxidant and anti-inflammatory that protect cells from destructive effect of elevated ROS and accelerate wound healing. Polygalacturonic acid nanoparticles also displays anti-bacterial activity.
Others  
Inflammation or Immune System Disease  
/
HY-P3159 VPM peptide
VPM peptide is a dithiol protease-cleavable peptide cross-linker. VPM peptide can be incorporated into the backbone of the PEG-diacrylate (PEG-DA) macromer to form PEG hydrogel.
Biochemical Assay Reagents  
/
HY-P99547 Trastuzumab duocarmazine
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas.
Antibody-Drug Conjugates (ADCs)  
/
HY-W763582A GelMA, 60% methacrylation
GelMA (Gelatin Methacryloyl), 60% methacrylation, is a derivative obtained by the reaction of Methacrylic anhydride (MA) (HY-W017330) and gelatin. GelMA exhibits excellent biocompatibility, biodegradability, and moldability. GelMA can be photocrosslinked into hydrogels and can be used for research in regeneration of tissues, such as skin, tendon, bone, cartilage, blood vessel, and cardiovascular system. GelMA hydrogel also can be used for research on drug delivery, organ-on-a-chip, and biosensing.
Biochemical Assay Reagents  
/
HY-W763582 GelMA, 30% methacrylation
GelMA (Gelatin Methacryloyl), 30% methacrylation, is a derivative obtained by the reaction of Methacrylic anhydride (MA) (HY-W017330) and gelatin. GelMA exhibits excellent biocompatibility, biodegradability, and moldability. GelMA can be photocrosslinked into hydrogels and can be used for research in regeneration of tissues, such as skin, tendon, bone, cartilage, blood vessel, and cardiovascular system. GelMA hydrogel also can be used for research on drug delivery, organ-on-a-chip, and biosensing.
Biochemical Assay Reagents  
/
HY-Y0873O PEG35000
PEG35000 is a polyethylene glycol with a molecular weight of 35,000 that can be used as a carrier material and modifier in drug delivery systems.
Environmental Pollutants   Biochemical Assay Reagents  
/
HY-P5423 GALA
GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. GALA significantly promotes the cytosolic release of cargos carried by exosomes, plasmids and liposomes, effectively enhances gene transfection efficiency, and drives gene knockdown of functional macromolecules (such as siRNA) in alveolar epithelial cells (with no significant cytotoxicity at effective concentrations). GALA serves as a critical tool for studies on lung cancer metastasis (e.g., melanoma lung metastasis) and lung-targeted drug delivery systems.
Exosomes   Liposome  
Metastatic Melanoma  
/
HY-W110542G Poly(ethylene glycol) diacrylate (MW 6000)
Poly(ethylene glycol) diacrylate (PEGDA) (MW 6000) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 6000) can be used as a building material for wound dressing hydrogels.
Biochemical Assay Reagents  
/
HY-156829B PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1)
PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors. The gelation temperature varies with concentration. The gelation temperature varies with the concentration; the higher the concentration, the lower the gelation temperature.
Biochemical Assay Reagents  
/
HY-P990685 Romiplostim
Romiplostim is an Fc-peptide fusion protein mimetic of TPO (thrombopoietin protein) and also a c-Mpl agonist. Romiplostim binds to c-Mpl, stimulates megakaryocyte-mediated thrombopoiesis, and activates the same downstream signaling pathways as endogenous TPO. Romiplostim is applicable to research related to hematopoietic acute radiation syndrome and chronic immune thrombocytopenia.
Cyclin G-associated Kinase (GAK)  
Platelet Disease  
/
HY-D1711 MHI-148
MHI-148 is a near-infrared heptamethine cyanine dye with tumor-targeting properties for cancer detection, diagnosis and research. MHI-148 is immediately taken up and accumulated by lysosomes and mitochondria of tumor cells, but not in lysosomes and mitochondria of normal cells.
Fluorescent Dye  
Cancer  
/
HY-170554 ABBV-706
ABBV-706 is a SEZ6-targeted topoisomerase 1 inhibitor Antibody-Drug Conjugates (ADCs), which is composed of the Linker-Payload conjugation (HY-148820) and the Anti-SEZ6 Antibody (SC17) (HY-P991041). ABBV-706 can inhibit cancer cells proliferation and induce DNA damage and G2/M arrest. ABBV-706 exhibits high efficacy against small cell lung cancer (SCLC), neuroendocrine tumors (NENs) and central nervous system (CNS) tumors.
Antibody-Drug Conjugates (ADCs)   Topoisomerase   DNA/RNA Synthesis  
CNS Neoplasm   Small Cell Lung Cancer  
/
HY-P99175 KWAR 23
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Species: Human

CD47  
Cancer  
/
HY-13674 Maytansine
Maytansine is a highly potent microtubule-targeted compound that induces mitotic arrest and kills tumor cells at subnanomolar concentrations.
Microtubule/Tubulin  
Lung Cancer  
/
HY-P1120 WKYMVm
WKYMVm is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs. WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor.
Formyl Peptide Receptor (FPR)   PERK   Apoptosis  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
/
HY-P991097 Pumitamig
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

Species: Human

VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-W011696 Oleylamine, 80-90%
Oleylamine, 80-90% (cis-1-Amino-9-octadecene, 80-90%) is a multifunctional reagent used for metal ion coordination and nanoparticle surface modification, and acts as a solvent, surfactant and reducing agent in the synthesis of metal oxide nanoparticles. Oleylamine, 80-90% regulates nanoparticle morphology, magnetization intensity and water proton relaxation rate via thiol-ene "click" reaction, and enhances the colloidal stability of nanoparticles in organic reagents. Oleylamine, 80-90% is mainly used in research and applications in fields such as nanomaterial synthesis, biomedical imaging (MRI contrast agents, fluorescent probes), cancer cell targeting and drug delivery.
Environmental Pollutants   Biochemical Assay Reagents  
Cancer  
/
HY-P990688 Xaluritamig
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-K2033 OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology to achieve highly efficient nucleic acid(eg. pDNA、mRNA、sgRNA、siRNA) delivery into Jurkat cells. It is designed for in vitro transfection of Jurkat cells and is well suited for applications in immunotherapy, tumor immunology, and other immune cell-related research.

Cell Biology Cell Culture Cell Transfection

/
HY-K2034 OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies.

Cell Biology Cell Culture Cell Transfection

/
HY-K2035 Fluc mRNA (N1-Me-pUTP)

MCE Fluc mRNA (N1-Me-pUTP) is widely used for evaluating lipid nanoparticle (LNP) delivery efficiency, validating mRNA transfection reagents, assessing in vitro and in vivo mRNA expression, IVIS bioluminescence imaging, and screening novel nucleic acid delivery systems. It is commonly used as a positive control or reporter mRNA.

Cell Biology Cell Culture Cell Transfection

/
HY-K3122 Dry Plant-Derived Extracellular Vesicle Isolation and Purification Kit

MCE Dry Plant-Derived Extracellular Vesicle Isolation and Purification Kit is specifically optimized for dried plant samples. It facilitates the efficient release of vesicles from plant tissues and employs an optimized extraction and purification system to remove non-vesicular components such as polysaccharides and phenolic compounds, thereby enabling the efficient extraction and purification of plant-derived vesicles. The isolated plant-derived vesicles can be used for downstream applications including transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), Western blotting, qPCR, cell-based studies, and animal experiments.

Cell Biology Cell Analysis Exosome Isolation, Purification and Detection

/
HY-K3123 Succulent Plant-Derived Extracellular Vesicle Isolation and Purification Kit

MCE Succulent Plant -Derived Extracellular Vesicle Isolation and Purification Kit is specifically optimized for succulent plant samples. It facilitates the efficient release of vesicles from plant tissues and employs an optimized extraction and purification system to remove non-vesicular components such as polysaccharides and phenolic compounds, thereby enabling the efficient extraction and purification of plant-derived vesicles. The isolated plant-derived vesicles can be used for downstream applications including transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), Western blotting, qPCR, cell-based studies, and animal experiments.

Cell Biology Cell Analysis Exosome Isolation, Purification and Detection

/
HY-K3124 Macrofungal-Derived Extracellular Vesicle Isolation and Purification Kit

MCE Macrofungal-Derived Extracellular Vesicle Isolation and Purification Kit is specifically optimized for fungal fruiting body samples. The optimized extraction system facilitates the release of EVs from fungal tissues, while the purification system effectively removes polysaccharides, proteins, phenolic compounds, terpenoids, and other non-vesicular components, enabling efficient isolation and purification of fungal EVs. The isolated macrofungal-derived vesicles can be used for downstream applications including transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), Western blotting, qPCR, cell-based studies, and animal experiments.

Cell Biology Cell Analysis Exosome Isolation, Purification and Detection

/

Keywords

drug delivery systems | cancer immunotherapy | nanoparticles | hydrogels | tumor targeting | immune agonists